October 29, 2021
09:00 - 09:30 BST
Weight gain following antiretroviral therapy initiation is common and may represent a "return to health" for some patients. However, others experience severe weight gain that exceeds what could reasonably be considered healthy. Simultaneously, worldwide obesity prevalence is increasing. Recently, some integrase strand transfer inhibitors and tenofovir alafenamide have been implicated in greater weight gain than other antiretroviral regimens. Mechanisms and clinical significance of any differential weight gain, however, are not well understood. This talk will review the available literature on this topic, identify gaps and propose future directions.
Speaker: Jordan E. Lake, United States